UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $1.33 Million Stock Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Vir Biotechnology, Inc. (NASDAQ:VIR) by 29.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 181,325 shares of the company’s stock after buying an additional 40,954 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.13% of Vir Biotechnology worth $1,331,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Vir Biotechnology in the 4th quarter valued at about $42,000. SBI Securities Co. Ltd. bought a new stake in Vir Biotechnology in the fourth quarter valued at approximately $60,000. PNC Financial Services Group Inc. increased its position in Vir Biotechnology by 31.8% during the 4th quarter. PNC Financial Services Group Inc. now owns 8,288 shares of the company’s stock valued at $61,000 after purchasing an additional 1,999 shares during the period. KBC Group NV increased its position in Vir Biotechnology by 136.5% during the 4th quarter. KBC Group NV now owns 8,970 shares of the company’s stock valued at $66,000 after purchasing an additional 5,177 shares during the period. Finally, CIBC Asset Management Inc bought a new position in Vir Biotechnology during the 4th quarter worth approximately $74,000. Institutional investors and hedge funds own 65.32% of the company’s stock.

Insider Transactions at Vir Biotechnology

In other news, CEO Backer Marianne De sold 79,712 shares of Vir Biotechnology stock in a transaction dated Thursday, April 3rd. The shares were sold at an average price of $5.95, for a total transaction of $474,286.40. Following the completion of the transaction, the chief executive officer now directly owns 769,505 shares in the company, valued at $4,578,554.75. This trade represents a 9.39% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 16.00% of the stock is owned by insiders.

Analysts Set New Price Targets

VIR has been the topic of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $110.00 price objective on shares of Vir Biotechnology in a research note on Friday, February 28th. Barclays upped their price target on shares of Vir Biotechnology from $26.00 to $31.00 and gave the company an “overweight” rating in a research report on Friday, February 28th. The Goldman Sachs Group lowered their price objective on Vir Biotechnology from $28.00 to $21.00 and set a “buy” rating for the company in a research report on Thursday, April 17th. Finally, Needham & Company LLC restated a “buy” rating and set a $14.00 target price on shares of Vir Biotechnology in a research report on Thursday, May 22nd. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $32.86.

Vir Biotechnology Trading Up 5.8%

Shares of NASDAQ VIR opened at $5.45 on Monday. The firm has a market capitalization of $753.40 million, a P/E ratio of -1.39 and a beta of 1.24. The firm’s 50-day moving average price is $5.37 and its 200-day moving average price is $7.44. Vir Biotechnology, Inc. has a 1-year low of $4.32 and a 1-year high of $14.45.

Vir Biotechnology (NASDAQ:VIR) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.05). The firm had revenue of $3.03 million for the quarter, compared to analyst estimates of $8.59 million. Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. The firm’s quarterly revenue was down 94.6% compared to the same quarter last year. During the same period last year, the company posted ($0.48) earnings per share. Equities research analysts forecast that Vir Biotechnology, Inc. will post -3.92 EPS for the current year.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).